Converge Bio, the AI platform for accelerated drug discovery and development, announced today $25 million in Series A funding, bringing its total raised to $30 million. The round was led by Bessemer ...
AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback